Median number of T-NK and NK lymphocytes in 43 patients with Ph⁺ ALL enrolled in the GIMEMA LAL2116 D-ALBA protocol during blinatumomab administration. PB samples were tested for T-NK (A) and NK (B) lymphocytes before starting blinatumomab (T0) and after the first (T1), second (T2), third (T3), fourth (T4), and fifth (T5) cycle. Box plots represent the median (line), interquartile range (top and bottom of box), and minimum and maximum values (whiskers). °Outliers. *P < .05; **P < .01. PB, peripheral blood.